`
`Apotex Launches First Generic Version of Merck's Nasonex®
`
`March 24, 2016
`For Immediate Release
`
`Apotex Launches First Generic Version of Merck's Nasonex®
`
`Toronto , ON- Apotex Inc. announced today that it has launched the first generic version of Merck's Nason ex® nasal spray (mometasone
`furoate monohydrate) in the United States.
`
`Apotex's mometasone furoate nasal spray is a once-daily anti-allergen indicated for treatment of nasal congestion . According to IMS Health ,
`Nasonex® had approximately $955.5 million in sales in the 12 months ending January 2016.
`
`"We are very pleased to make a more affordable version of this important allergy medicine available to the US public. Apotex is dedicated to
`bringing high quality versions of complex generic products to market, and we are delighted that these efforts will generate substantial
`savings for the US health care system," said Apotex Chief Executive Officer and President, Dr. Jeremy B. Desai. "The amount of work
`required by all stakeholders to enable the launch of a first generic of this complexijy cannot be overstated , and we appreciate the role of
`everyone involved , induding the FDA who provided steady guidance throughout the development process," Desai added .
`
`FDA's approval of the company's generic version of Nasonex® fo llows Apotex's successfu l Hatch-V\Iaxman challenge of US Patent No.
`6,127,353 (the '353 patent), which Merck daimed covered the active ingredient. In June 2012 , the US District Court for the District of New
`Jersey found that Apotex's product did not infringe the '353 patent. The decision was upheld in June 2013 by the Federal Circuit.
`
`About Apotex
`
`Apotex is the 7th largest generic pharmaceutica l company globally (according to IMS HeaHh) with over 10,000 employees and estimated
`sales of approximately $2 billion. The company's US headquarters is based in Weston, Florida. With its worldwide manufacturing sites,
`Apotex can produce up to 24 billion dosages per year. It produces 300 medicines in 4,000 dosages and formats that are exported to 115
`countries. It has 500 products under development and will spend $2 billion over the next 10 years on research and development.
`
`-30-
`
`Mr. Steve Guili
`Director, Government Affairs
`Tel: 954-384-3984
`Cell: 954-224-5142
`
`All other brand or product names located in this site are Trademarks of their respective holders. © Apotex Inc. 2016. All rights reserved.
`
`http://www.apotex.com /global/about/press/20160324.asp
`
`PLAINTIFFS'
`TRIAL EXHIBIT
`PTX0409
`
`1/1
`
`MEDA_APTX03503075
`
`PTX0409-0000 1
`
`1
`
`CIP2101
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`